Abstract
Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction. Platelets play a crucial role in thrombosis and haemostasis, which can be either beneficial or deleterious, depending on the circumstances. Platelet hyperreactivity is a multifactor process depending on genetic polymorphism, pathological state and lifestyle; it contributes to the activation of the thrombotic cascade. Under pathophysiological conditions platelets activation plays a critical role in arterial thrombosis including platelets aggregation, the basis of destabilization of coronary plaque. Despite the benefits observed in outcome when primary angioplasty is compared with thrombolysis for the treatment of acute myocardial infarction there is still some room for improvement; unfortunately the restoration of an “optimal” epicardial flow is not always related to an “optimal” myocardial reperfusion. In the recent, past several studies have shown significant benefits with the administration of glycoprotein IIb/IIIa inhibitors. Thus, the aim of the present review is to perform an update on factors associated with platelets hyperactivity and on adjunctive glycoprotein IIb – IIIa inhibitors in primary angioplasty.
Keywords: STEMI, PCI, GP IIb/IIIa, Abciximab, Tifofiban, Eptifibatide, no reflow phenomenon, microvascular disease, sistolic dysfunction, coronary thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Volume: 9 Issue: 2
Author(s): Andrea Rognoni, Alessandro Lupi, Gioel Gabrio Secco, Chiara Cavallino, Mara Sansa, Maurizio Lazzero and Angelo Sante Bongo
Affiliation:
Keywords: STEMI, PCI, GP IIb/IIIa, Abciximab, Tifofiban, Eptifibatide, no reflow phenomenon, microvascular disease, sistolic dysfunction, coronary thrombosis
Abstract: Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction. Platelets play a crucial role in thrombosis and haemostasis, which can be either beneficial or deleterious, depending on the circumstances. Platelet hyperreactivity is a multifactor process depending on genetic polymorphism, pathological state and lifestyle; it contributes to the activation of the thrombotic cascade. Under pathophysiological conditions platelets activation plays a critical role in arterial thrombosis including platelets aggregation, the basis of destabilization of coronary plaque. Despite the benefits observed in outcome when primary angioplasty is compared with thrombolysis for the treatment of acute myocardial infarction there is still some room for improvement; unfortunately the restoration of an “optimal” epicardial flow is not always related to an “optimal” myocardial reperfusion. In the recent, past several studies have shown significant benefits with the administration of glycoprotein IIb/IIIa inhibitors. Thus, the aim of the present review is to perform an update on factors associated with platelets hyperactivity and on adjunctive glycoprotein IIb – IIIa inhibitors in primary angioplasty.
Export Options
About this article
Cite this article as:
Rognoni Andrea, Lupi Alessandro, Gabrio Secco Gioel, Cavallino Chiara, Sansa Mara, Lazzero Maurizio and Sante Bongo Angelo, Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (2) . https://dx.doi.org/10.2174/187152511796196524
DOI https://dx.doi.org/10.2174/187152511796196524 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Cucurbita Argyrosperma as Anti-Angiogenic Chemopreventive,
Anti-Diabetic, Anti-Carcinogenic, and Anti-microbial Therapy
Current Traditional Medicine Epidemiological Characteristics of 64 Covid-19 Patients in Errachidia Province (Darâa-Tafilalet region), Morocco: A Retrospective Analysis
Reviews on Recent Clinical Trials 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued) Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Mexiletine Metabolites: A Review
Current Medicinal Chemistry Electroanalytical Methods for Determination of Calcium Channel Blockers
Current Analytical Chemistry Highest Mortality During the Last Year Before and the First Year After Start of Dialysis Treatment in Type 2 Diabetic Patients with Nephropathy
Current Diabetes Reviews Effects of Lipid-Lowering Drugs on Adiponectin
Current Vascular Pharmacology Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence
Current Cardiology Reviews Synthesis and Bioactivities of 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors
Medicinal Chemistry Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Sterol Biosynthesis Pathway as an Alternative for the Anti-Protozoan Parasite Chemotherapy
Current Medicinal Chemistry Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry Identification and Quantitation of Some Characteristic Phenolic Compounds in Elderberry Juice by HPLC with Coulometric Electrode Array Detection
Current Bioactive Compounds Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients
Current Proteomics Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets